Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

This study aims to evaluate whether \^68Ga-TROP2 PET/CT, combined with \^18F-FDG PET/CT, can predict the efficacy of anti-TROP2 antibody-drug conjugates in patients with advanced HER2-negative breast cancer. Baseline and dynamic imaging parameters will be used to develop prediction models (primary endpoint: AUC), and their associations with clinical outcomes and tumor TROP2 status will be explored.

NCT Number	NCT07471776
Lead Sponsor	Fudan University
Conditions	Metastatic Breast Cancer ( HER2 Negative)
Enrollment	45 participants
Start Date	2026-03-11
Primary Completion	2028-03-11 (estimated)
Study Completion	2029-03-11 (estimated)
Updated on ClinicalTrials.gov	2026-03-13